Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech's sales for surgical soft tissue repair products experienced a significant year-over-year growth of 24%, reaching $23.4 million, largely driven by strong demand for its CellerateRX Surgical Powder and BIASURGE Surgical Solution. The company has shown a strong trajectory for future revenues, with top-line growth projections of 3-5% for 2025 and an anticipated 13-17% growth for 2026, alongside the expected profitability from continuing operations achieved in the third quarter of 2025. Additionally, strategic partnerships, such as the newly secured contract with Vizient, enhance access to Sanara's products and support the company's ongoing efforts to improve operational efficiency and expand its market presence.

Bears say

Sanara MedTech Inc. reported net revenue of $26.3 million, indicating a year-over-year growth of 21.5%, yet this figure fell short of the projected $26.7 million, highlighting potential weaknesses in revenue generation. The company faces several risks, including the possibility of lower-than-expected revenue growth, challenges in acquiring new customers, difficulties in launching new products, and prospects of dilution, which could hinder its overall performance. Additionally, the reduction of the enterprise value to revenue multiple from 4.3x to 3.0x reflects a reevaluation of the company's market position following the exclusion of telehealth from its business strategy.

SMTI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Strong Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.